Atorvastatin attenuates testosterone-induced benign prostatic hyperplasia in rats: role of peroxisome proliferator-activated receptor-γ and cyclo-oxygenase-2.

about

Atorvastatin attenuates testosterone-induced benign prostatic hyperplasia in rats: role of peroxisome proliferator-activated receptor-γ and cyclo-oxygenase-2.

Item

http://www.wikidata.org/entity/Q48242893

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Atorvastatin attenuates testos ...... eptor-γ and cyclo-oxygenase-2.

@en

Atorvastatin attenuates testos ...... eptor-γ and cyclo-oxygenase-2.

@nl

type

Item

label

Atorvastatin attenuates testos ...... eptor-γ and cyclo-oxygenase-2.

@en

Atorvastatin attenuates testos ...... eptor-γ and cyclo-oxygenase-2.

@nl

prefLabel

Atorvastatin attenuates testos ...... eptor-γ and cyclo-oxygenase-2.

@en

Atorvastatin attenuates testos ...... eptor-γ and cyclo-oxygenase-2.

@nl

P1476

Atorvastatin attenuates testos ...... ceptor-γ and cyclo-oxygenase-2

@en

P2093

Charles C Anunobi

http://www.w3.org/2001/XMLSchema#string

Habeeb K Tijani

http://www.w3.org/2001/XMLSchema#string

Olufunke O Dosumu

http://www.w3.org/2001/XMLSchema#string

Tolulope O Oshodi

http://www.w3.org/2001/XMLSchema#string

P2860

Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent

Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.

Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence

Oxidative stress promotes benign prostatic hyperplasia.

IL-1 induces IGF-dependent epithelial proliferation in prostate development and reactive hyperplasia

Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling in prostate cancer.

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.

P304

652-662

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/FCP.12301

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ismail Ogunbayode Ishola

P577

2017-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28636803

http://www.w3.org/2001/XMLSchema#string